Tharimmune to Present at the Microcap Conference 2025: A Promising Biotech Stock to Watch

Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company focused on immunology and inflammation therapies, has announced its participation in The Microcap Conference 2025. The event will take place from January 28 to 30 in Atlantic City, New Jersey, providing an opportunity for the company to showcase its recent developments, growth strategy, and investment opportunities. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors on Thursday, January 30, at 10:00 AM Eastern Time in Studio 4 of the Borgata Hotel Casino & Spa.

Tharimmune's focus on immunology and inflammation therapies positions the company at the forefront of addressing unmet medical needs in these areas, which are prevalent in various diseases and conditions. By developing innovative therapeutic candidates like TH104 and TH023, Tharimmune is well-positioned to capture significant market opportunities in these therapeutic areas.

Tharimmune's lead clinical asset, TH104, targets chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. This focus on rare and orphan diseases allows Tharimmune to tap into the growing market for orphan drugs, which has seen significant growth in recent years. According to a report by Grand View Research, the global orphan drugs market size was valued at USD 114.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 10.6% from 2021 to 2028 (Source: [Grand View Research](https://www.grandviewresearch.com/industry-analysis/orphan-drugs-market)).

Tharimmune's expanded pipeline includes TH023, an oral TNF-alpha inhibitor, which offers a new approach to treating autoimmune diseases. This diversified pipeline allows the company to explore multiple therapeutic areas and indications, reducing the risk associated with a single product. Additionally, Tharimmune is advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors, further expanding its potential market reach.



Tharimmune's strategic partnerships, such as the license agreement with OmniAb, Inc. for antibody discovery technology, and the acquisition of a global license and partnership with Intract Pharma to develop an oral formulation of infliximab, enable the company to leverage cutting-edge technology to enhance its drug discovery and development capabilities. These collaborations can accelerate Tharimmune's growth and pipeline expansion, ultimately leading to more effective and innovative therapies.



Tharimmune's focus on immunology and inflammation therapies presents attractive investment opportunities for several reasons:

* Growing market demand for innovative therapies in these therapeutic areas.
* Strong analyst consensus, with a "Strong Buy" rating and a 12-month stock price forecast of $17.0, indicating significant upside potential (721.26%).
* Positive clinical data and regulatory feedback, demonstrating the potential of Tharimmune's pipeline and validating the company's approach to drug development.
* A well-funded and experienced management team, as evidenced by the company's recent private placement of $2.02 million, which will support the advancement of its development programs.

In conclusion, Tharimmune's participation in The Microcap Conference 2025 provides an opportunity for the company to showcase its recent developments, growth strategy, and investment opportunities. With a strong focus on immunology and inflammation therapies, a diversified pipeline, and strategic partnerships, Tharimmune is well-positioned to capture significant market opportunities and drive future growth in the biotechnology sector. Investors should consider Tharimmune as a promising biotech stock to watch in the coming months and years.